These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

562 related articles for article (PubMed ID: 29777201)

  • 1. Novel-smoothened inhibitors for therapeutic targeting of naïve and drug-resistant hedgehog pathway-driven cancers.
    Li QR; Zhao H; Zhang XS; Lang H; Yu K
    Acta Pharmacol Sin; 2019 Feb; 40(2):257-267. PubMed ID: 29777201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CDK7 inhibition suppresses aberrant hedgehog pathway and overcomes resistance to smoothened antagonists.
    Liu F; Jiang W; Sui Y; Meng W; Hou L; Li T; Li M; Zhang L; Mo J; Wang J; Zhao Y; Zhang L; Ma J; Tang Y
    Proc Natl Acad Sci U S A; 2019 Jun; 116(26):12986-12995. PubMed ID: 31182587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo inhibition of breast cancer cell growth by targeting the Hedgehog/GLI pathway with SMO (GDC-0449) or GLI (GANT-61) inhibitors.
    Benvenuto M; Masuelli L; De Smaele E; Fantini M; Mattera R; Cucchi D; Bonanno E; Di Stefano E; Frajese GV; Orlandi A; Screpanti I; Gulino A; Modesti A; Bei R
    Oncotarget; 2016 Feb; 7(8):9250-70. PubMed ID: 26843616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ABT-199 inhibits Hedgehog pathway by acting as a competitive inhibitor of oxysterol, rather as a BH3 mimetic.
    Wang J; Zhang Y; Huang WJ; Yang J; Tang WG; Huang TM; Tan WF
    Acta Pharmacol Sin; 2021 Jun; 42(6):1005-1013. PubMed ID: 32855528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro.
    You M; Varona-Santos J; Singh S; Robbins DJ; Savaraj N; Nguyen DM
    J Thorac Cardiovasc Surg; 2014 Jan; 147(1):508-16. PubMed ID: 24094913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of [1,2,4]triazolo[4,3-a]pyridines as potent Smoothened inhibitors targeting the Hedgehog pathway with improved antitumor activity in vivo.
    Tian N; Wu H; Zhang H; Yang D; Lv L; Yang Z; Zhang T; Quan D; Zhou L; Xie Y; Xu Y; Wei N; Zhang J; Chen M; Schmitz JC; Tian Y; Wu S
    Bioorg Med Chem; 2020 Aug; 28(16):115584. PubMed ID: 32690258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance.
    Dijkgraaf GJ; Alicke B; Weinmann L; Januario T; West K; Modrusan Z; Burdick D; Goldsmith R; Robarge K; Sutherlin D; Scales SJ; Gould SE; Yauch RL; de Sauvage FJ
    Cancer Res; 2011 Jan; 71(2):435-44. PubMed ID: 21123452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition mechanism exploration of investigational drug TAK-441 as inhibitor against Vismodegib-resistant Smoothened mutant.
    Ishii T; Shimizu Y; Nakashima K; Kondo S; Ogawa K; Sasaki S; Matsui H
    Eur J Pharmacol; 2014 Jan; 723():305-13. PubMed ID: 24291104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of Hedgehog-dependent tumors and cancer stem cells by a newly identified naturally occurring chemotype.
    Infante P; Alfonsi R; Ingallina C; Quaglio D; Ghirga F; D'Acquarica I; Bernardi F; Di Magno L; Canettieri G; Screpanti I; Gulino A; Botta B; Mori M; Di Marcotullio L
    Cell Death Dis; 2016 Sep; 7(9):e2376. PubMed ID: 27899820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, Synthesis, and Structure-Activity Relationship of Tetrahydropyrido[4,3-d]pyrimidine Derivatives as Potent Smoothened Antagonists with in Vivo Activity.
    Lu W; Liu Y; Ma H; Zheng J; Tian S; Sun Z; Luo L; Li J; Zhang H; Yang ZJ; Zhang X
    ACS Chem Neurosci; 2017 Sep; 8(9):1980-1994. PubMed ID: 28618224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of pseudolaric acid B as a novel Hedgehog pathway inhibitor in medulloblastoma.
    Wei SF; He DH; Zhang SB; Lu Y; Ye X; Fan XZ; Wang H; Wang Q; Liu YQ
    Biochem Pharmacol; 2021 Aug; 190():114593. PubMed ID: 33964282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DYRK1B as therapeutic target in Hedgehog/GLI-dependent cancer cells with Smoothened inhibitor resistance.
    Gruber W; Hutzinger M; Elmer DP; Parigger T; Sternberg C; Cegielkowski L; Zaja M; Leban J; Michel S; Hamm S; Vitt D; Aberger F
    Oncotarget; 2016 Feb; 7(6):7134-48. PubMed ID: 26784250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel hedgehog inhibitor for the treatment of hematological malignancies.
    Lin P; He Y; Chen G; Ma H; Zheng J; Zhang Z; Cao B; Zhang H; Zhang X; Mao X
    Anticancer Drugs; 2018 Nov; 29(10):995-1003. PubMed ID: 30106753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of Hedgehog Signaling in Fibroblasts, Pancreatic, and Lung Tumor Cells by Oxy186, an Oxysterol Analogue with Drug-Like Properties.
    Wang F; Stappenbeck F; Parhami F
    Cells; 2019 May; 8(5):. PubMed ID: 31137846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway.
    Ramaswamy B; Lu Y; Teng KY; Nuovo G; Li X; Shapiro CL; Majumder S
    Cancer Res; 2012 Oct; 72(19):5048-59. PubMed ID: 22875023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. L-4, a Well-Tolerated and Orally Active Inhibitor of Hedgehog Pathway, Exhibited Potent Anti-tumor Effects Against Medulloblastoma
    Zhu M; Wang H; Wang C; Fang Y; Zhu T; Zhao W; Dong X; Zhang X
    Front Pharmacol; 2019; 10():89. PubMed ID: 30846937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to inhibition of smoothened in diverse epithelial cancer cells that lack smoothened or patched 1 mutations.
    Galimberti F; Busch AM; Chinyengetere F; Ma T; Sekula D; Memoli VA; Dragnev KH; Liu F; Johnson KC; Guo Y; Freemantle SJ; Andrew AS; Greninger P; Robbins DJ; Settleman J; Benes C; Dmitrovsky E
    Int J Oncol; 2012 Nov; 41(5):1751-61. PubMed ID: 22923130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling.
    Ibuki N; Ghaffari M; Pandey M; Iu I; Fazli L; Kashiwagi M; Tojo H; Nakanishi O; Gleave ME; Cox ME
    Int J Cancer; 2013 Oct; 133(8):1955-66. PubMed ID: 23564295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Super-Enhancer-Driven Transcriptional Dependencies Suppresses Aberrant Hedgehog Pathway Activation and Overcomes Smoothened Inhibitor Resistance.
    Sui Y; Wang T; Mei Y; Zhu Y; Jiang W; Shen J; Yan S; Lu W; Zhao K; Mo J; Wang C; Tang Y
    Cancer Res; 2024 Aug; 84(16):2690-2706. PubMed ID: 38775809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural optimization on a virtual screening hit of smoothened receptor.
    Song S; Jiang J; Zhao L; Wang Q; Lu W; Zheng C; Zhang J; Ma H; Tian S; Zheng J; Luo L; Li Y; Yang ZJ; Zhang X
    Eur J Med Chem; 2019 Jun; 172():1-15. PubMed ID: 30939349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.